ArticleInternational journal of oncology2015

Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.

Gabriel G Vega et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.